INTRODUCTION
suggested that the treatment must be individualized, assessing the location, the size of the lesion, the presence of ulceration or the involvement of other organs [1] [2] [3] .
Clinical Cases
We present seven patients, treated at the pediatric surgery service with a clinical diagnosis of benign hemangioma of childhood. The parents were interviewed about important medical history and a complete physical examination and injury was performed. The start of medical management with propranolol at a dose of 2 mg/kg/day was proposed, in accordance with the international clinical practice guidelines for this pathology, all of them agreed. The ages of our patients ranged between 6 months and 6 years of age (5 female and 2 male) (Figures 1 and 2 ). The other three cases corresponded to: male 6 months-old with back lesion; one year-old female with lesion in neck and supraciliary region of the left eye, and female of two years of age with neck lesion (without images).
DISCUSSION
The prevalence of infantile hemangiomas ranges from 4 to 5%. They are the most common benign tumors at this age and most of them regress without requiring treatment. Up to 80%
of the hemangiomas reach their final size at three months of age [4] . Other treatment modalities that have been used are: the pulsed laser, ideal in precursor lesions that manifest as reddish spots or to remove residual telangiectasias, however its greatest use is in ulcerated hemangiomas and its effectiveness is not effective in lesions deep, since the penetration of the laser is 1.2 mm to 1.5 mm [8] .
Propranolol has been prescribed for 40 years, within its effects the vasoconstriction it has been proposed as the direct effect on hemangiomas, reflected as a change of coloration in the lesion, inhibits angiogenesis by decreasing the expression of proangiogenic factors, the growth factor of fibroblasts and vascular endothelial growth factor, and produces the apoptosis of endothelial cells, resulting in regression of the lesion [9] .
For its use there are still undefined criteria, such as the duration of the treatment, which has been suggested to be at least 6 months. There is a recent consensus that suggests a dose of 1 mg/ kg/day to 3 mg/ kg/day, starting with a dose of 1 mg/kg/day, increasing progressively until reaching the desired dose, prior to the start of treatment, serum glucose must be determined, cardiological assessment, insist on bronchial problems where bronchospasm can be exacerbated.
The absence of response should be evaluated after four weeks with treatment ≥2 mg/kg/day where we will consider these cases as resistant to treatment [10] .
This last alteration of treatment has come to revolutionize the therapeutic approach of infantile hemangiomas, for having a high response rate with very few adverse effects, we must now consider propranolol the first line medication for its efficacy and safety in pediatric age 6 From the discovery of propranolol as an effective treatment for this pathology, multiple studies have been published supporting this medical management with different results about this treatment [11] [12] [13] [14] [15] [16] [17] . 
CONCLUSION

